Connect with us

Hi, what are you looking for?

Wednesday, Feb 12, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.

Beverages

Quantum BioPharma soars on clinical trial success with ‘unbuzzd’ hangover cure supplement

Shares are currently up by over 110% on the Nasdaq

Quantum BioPharma soars on clinical trial success with 'unbuzzd' hangover cure supplement
'unbuzzd' can help sober you up and keep you going. Image credit: Celly Nutrition -- a partner of Quantum BioPharma

Quantum BioPharma Ltd (CNSX: QNTM) (NASDAQ: QNTM) (FRA: 0K91) flew on Tuesday after revealing that its sober up hangover cure supplement had demonstrated multiple successes in a clinical assessment. The company’s share price rose more than two-fold.

In the clinical trial, Quantum’s “unbuzzd” product proved its ability to rapidly reduce blood alcohol concentration (BAC). It showed remarkable improvements in lessening intoxication and enhancing alertness among those who took it too, in comparison to the placebo group.

“The rate at which BAC was lowered was, on average for most participants, more than 40 per cent faster within 30 minutes of consuming unbuzzd compared to control subjects,” the company specified.

Study participants who ingested the powdered blend of vitamins and minerals also reported a substantial reduction in unpleasant hangover symptoms and no nasty side effects of any kind. They had a 67 per cent reduction in headache symptoms four hours after consumption, on average.

Ingredients in unbuzzd include green tea extract, milk thistle and the amino acid phenylalanine. It is currently available in a powered form, but Quantum is planning to put it into cans too.

The product initially launched on Amazon.com Inc (NASDAQ: AMZN) last year and will be making its way into major stores throughout the Americas in the near future.

“Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of BOC, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover,” chief executive Zeeshan Saeed said.

Read more: Light AI develops smartphone tech for diagnosing severe throat infection

Read more: Sleep technology helps UAE cycling team prepare for Tour de France

Quantum BioPharma tackles multiple sclerosis

The biopharmaceutical operator’s primary focus is its Lucid-MS drug.

Phase I in-human trials with this therapeutic have been completed, Quantum says. It has demonstrated significant potential for treating the central nervous system condition in multiple rodent studies. This condition impacts the brain and the spinal cord. It results in muscle weakness, loss of coordination, fatigue and other issues.

“Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse ‘myelin degradation,’ a cause for multiple sclerosis [MS], as well as other neurodegenerative diseases and conditions,” Quantum explained.

This remedy is patented in the United States and the European Union.

“Today there is no cure for MS,” the drug developer says. The aim of Quantum BioPharma’s game is to change that for millions of people suffering from the affliction.

 

Follow Mugglehead on X

Like Mugglehead on Facebook

Follow Rowan Dunne on X

rowan@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medical and Pharmaceutical

The stock was up by about 200% during early trading hours

Health & Wellness

MASH is a more severe form of metabolic dysfunction-associated steatotic liver disease formerly known as non-alcoholic fatty liver disease

Medical and Pharmaceutical

It will be issued within 3 months provided that there are no opposition filings made by third parties

Gold

A heap leach pad failure last February caused a catastrophic incident that killed 9 people